Literature DB >> 34631938

Does the Anti-Tau Strategy in Progressive Supranuclear Palsy Need to Be Reconsidered? Yes.

Alberto J Espay1, Kariem Ezzat2, Andrea Sturchio1,3.   

Abstract

Entities:  

Keywords:  disease modification; progressive supranuclear palsy; tau

Year:  2021        PMID： 34631938      PMCID： PMC8485621          DOI： 10.1002/mdc3.13324

Source DB:  PubMed          Journal:  Mov Disord Clin Pract        ISSN： 2330-1619


× No keyword cloud information.
  24 in total

1.  Failure of first anti-tau antibody in Alzheimer disease highlights risks of history repeating.

Authors:  Asher Mullard
Journal:  Nat Rev Drug Discov       Date:  2021-01       Impact factor: 84.694

Review 2.  Supersaturation is a major driving force for protein aggregation in neurodegenerative diseases.

Authors:  Prajwal Ciryam; Rishika Kundra; Richard I Morimoto; Christopher M Dobson; Michele Vendruscolo
Journal:  Trends Pharmacol Sci       Date:  2015-01-27       Impact factor: 14.819

Review 3.  Amyloid-β immunotherapy for alzheimer disease: Is it now a long shot?

Authors:  Francesco Panza; Madia Lozupone; Davide Seripa; Bruno P Imbimbo
Journal:  Ann Neurol       Date:  2019-01-28       Impact factor: 10.422

4.  Spatial patterns of the tau pathology in progressive supranuclear palsy.

Authors:  Richard A Armstrong; Nigel J Cairns
Journal:  Neurol Sci       Date:  2012-03-13       Impact factor: 3.307

5.  Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade.

Authors:  Clifford R Jack; David S Knopman; William J Jagust; Leslie M Shaw; Paul S Aisen; Michael W Weiner; Ronald C Petersen; John Q Trojanowski
Journal:  Lancet Neurol       Date:  2010-01       Impact factor: 44.182

6.  Progressive parkinsonism in older adults is related to the burden of mixed brain pathologies.

Authors:  Aron S Buchman; Lei Yu; Robert S Wilson; Sue E Leurgans; Sukriti Nag; Joshua M Shulman; Lisa L Barnes; Julie A Schneider; David A Bennett
Journal:  Neurology       Date:  2019-03-20       Impact factor: 9.910

Review 7.  Half a century of amyloids: past, present and future.

Authors:  Pu Chun Ke; Ruhong Zhou; Louise C Serpell; Roland Riek; Tuomas P J Knowles; Hilal A Lashuel; Ehud Gazit; Ian W Hamley; Thomas P Davis; Marcus Fändrich; Daniel Erik Otzen; Matthew R Chapman; Christopher M Dobson; David S Eisenberg; Raffaele Mezzenga
Journal:  Chem Soc Rev       Date:  2020-07-07       Impact factor: 54.564

8.  Tau mis-splicing correlates with motor impairments and striatal dysfunction in a model of tauopathy.

Authors:  Ana Damianich; Carolina Lucia Facal; Javier Andrés Muñiz; Camilo Mininni; Mariano Soiza-Reilly; Magdalena Ponce De León; Leandro Urrutia; German Falasco; Juan Esteban Ferrario; María Elena Avale
Journal:  Brain       Date:  2021-09-04       Impact factor: 13.501

Review 9.  The physiological roles of tau and Aβ: implications for Alzheimer's disease pathology and therapeutics.

Authors:  Sarah A Kent; Tara L Spires-Jones; Claire S Durrant
Journal:  Acta Neuropathol       Date:  2020-07-29       Impact factor: 15.887

10.  Accuracy of Tau Positron Emission Tomography as a Prognostic Marker in Preclinical and Prodromal Alzheimer Disease: A Head-to-Head Comparison Against Amyloid Positron Emission Tomography and Magnetic Resonance Imaging.

Authors:  Rik Ossenkoppele; Ruben Smith; Niklas Mattsson-Carlgren; Colin Groot; Antoine Leuzy; Olof Strandberg; Sebastian Palmqvist; Tomas Olsson; Jonas Jögi; Erik Stormrud; Hanna Cho; Young Hoon Ryu; Jae Yong Choi; Adam L Boxer; Maria L Gorno-Tempini; Bruce L Miller; David Soleimani-Meigooni; Leonardo Iaccarino; Renaud La Joie; Suzanne Baker; Edilio Borroni; Gregory Klein; Michael J Pontecorvo; Michael D Devous; William J Jagust; Chul Hyoung Lyoo; Gil D Rabinovici; Oskar Hansson
Journal:  JAMA Neurol       Date:  2021-08-01       Impact factor: 18.302
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.